These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12702133)

  • 1. Impact of highly active antiretroviral therapy on the occurrence of bacteraemia in HIV-infected patients and their epidemiologic characteristics.
    Meynard JL; Guiguet M; Fonquernie L; Lefebvre B; Lalande V; Honore I; Meyohas MC; Girard PM
    HIV Med; 2003 Apr; 4(2):127-32. PubMed ID: 12702133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreasing trends of bacteraemia among HIV-infected Ugandan adults: incidence, aetiology, clinical outcomes and effect of antiretroviral therapy in a semi-urban setting (2000-2008).
    Muyanja SZ; Larke N; Rutebarika D; Kaddu I; Nakubulwa S; Levin J; Grosskurth H; Miiro G
    Trop Med Int Health; 2011 Jun; 16(6):756-65. PubMed ID: 21392188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The incidence of and risk factors for MRSA bacteraemia in an HIV-infected cohort in the HAART era.
    Burkey MD; Wilson LE; Moore RD; Lucas GM; Francis J; Gebo KA
    HIV Med; 2008 Nov; 9(10):858-62. PubMed ID: 18754806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Grau I; Pallares R; Tubau F; Schulze MH; Llopis F; Podzamczer D; Liñares J; Gudiol F;
    Arch Intern Med; 2005 Jul; 165(13):1533-40. PubMed ID: 16009870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects induced by the introduction of highly active antiretroviral therapy (HAART) on disseminated bacterial infection during HIV disease].
    Manfredi R; Chiodo F
    Infez Med; 2002 Jun; 10(2):107-14. PubMed ID: 12702888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: the Nigerian experience.
    Erhabor O; Ejele OA; Nwauche CA
    Niger J Clin Pract; 2006 Dec; 9(2):128-33. PubMed ID: 17319344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study of highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients.
    Rajesh R; Vidyasagar S; Varma DM; Naik A; Hegde BM; Guddattu V; Kamath A
    Int J Risk Saf Med; 2013 Jan; 25(1):53-65. PubMed ID: 23442298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire.
    Losina E; Yazdanpanah Y; Deuffic-Burban S; Wang B; Wolf LL; Messou E; Gabillard D; Seyler C; Freedberg KA; Anglaret X
    Antivir Ther; 2007; 12(4):543-51. PubMed ID: 17668563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era.
    Vilchez RA; Finch CJ; Jorgensen JL; Butel JS
    Medicine (Baltimore); 2003 Mar; 82(2):77-81. PubMed ID: 12640183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study.
    Kohli R; Lo Y; Homel P; Flanigan TP; Gardner LI; Howard AA; Rompalo AM; Moskaleva G; Schuman P; Schoenbaum EE;
    Clin Infect Dis; 2006 Jul; 43(1):90-8. PubMed ID: 16758423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study.
    Matinella A; Lanzafame M; Bonometti MA; Gajofatto A; Concia E; Vento S; Monaco S; Ferrari S
    J Neurol; 2015 May; 262(5):1317-27. PubMed ID: 25877836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors and predictors of mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in HIV-infected patients.
    Tumbarello M; de Gaetano Donati K; Tacconelli E; Citton R; Spanu T; Leone F; Fadda G; Cauda R
    J Antimicrob Chemother; 2002 Sep; 50(3):375-82. PubMed ID: 12205062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
    López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
    J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
    Salmon-Céron D; Mazeron MC; Chaput S; Boukli N; Senechal B; Houhou N; Katlama C; Matheron S; Fillet AM; Gozlan J; Leport C; Jeantils V; Freymuth F; Costagliola D
    AIDS; 2000 May; 14(8):1041-9. PubMed ID: 10853987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.
    Dean GL; Edwards SG; Ives NJ; Matthews G; Fox EF; Navaratne L; Fisher M; Taylor GP; Miller R; Taylor CB; de Ruiter A; Pozniak AL
    AIDS; 2002 Jan; 16(1):75-83. PubMed ID: 11741165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.